Yi YM, Yang TY, Pan WM. Preparation and distribution of 5-fluorouracil 125I sodium alginate-bovine serum albumin nanoparticles. World J Gastroenterol 1999; 5(1): 57-60 [PMID: 11819388 DOI: 10.3748/wjg.v5.i1.57]
Corresponding Author of This Article
Yi-Mu Yi, Pharmaceutics Department of School of Pharmacy, Tongji Medical University, Wuhan 430030, Hubei Province, China
Article-Type of This Article
Original Articles
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 15, 1999; 5(1): 57-60 Published online Feb 15, 1999. doi: 10.3748/wjg.v5.i1.57
Table 1 Encapsulation efficiency of 5-FU in NP
Weight of drug added (g)
A value
Weight of drug encapsulated (g)
Encapsulation efficiency (%)
0.6162
0.679
0.208
33.8
0.6113
0.625
0.193
31.6
0.5917
0.676
0.195
32.9
Table 2 Rate of recovery of 5-FU
Weight of 5-FU added (g)
Weight of 5-FU determined (g)
Rate of recovery (%)
0.1348
0.1326
98.4
0.1463
0.1449
99.1
0.1429
0.1395
97.6
Table 3 Distribution of 125I sodium alginate-BSA NP in rats (n = 3, dosage 148 × 108 Bq per rat, po.)
Organ
Value of radioactive counting of 100mg tissue in 30s at different time points
1 h
4 h
8 h
16 h
24 h
36 h
Blood
502 ± 100
601 ± 135
373 ± 22
298 ± 19
191 ± 17
129 ± 23
Heart
436 ± 110(0.86)
801 ± 66(0.33)
265 ± 23(0.71)
230 ± 23(0.77)
190 ± 10(0.99)
87 ± 35(0.67)
Liver
436 ± 110(0.86)
908 ± 100(1.51)
777 ± 69(2.08)
405 ± 97(1.36)
226 ± 16(1.18)
153 ± 21(1.19)
Spleen
663 ± 140(1.32)
1029 ± 168(1.71)
834 ± 272(2.32)
436 ± 195(1.46)
233 ± 25(1.22)
169 ± 27(0.95)
Lungs
717 ± 314(1.42)
818 ± 172(1.36)
597 ± 121(1.60)
443 ± 31(1.49)
166 ± 4(0.87)
119 ± 27(0.92)
Kidneys
526 ± 139(1.05)
185 ± 39(0.14)
401 ± 71(1.08)
387 ± 105(1.30)
133 ± 13(0.69)
123 ± 14(0.95)
Brain
105 ± 31(0.21)
112 ± 49(0.19)
111 ± 47(0.30)
96 ± 27(0.32)
50 ± 5(0.26)
39 ± 11(0.30)
Stomach
89654 ± 7143
28674 ± 3647
8362 ± 1902
4641 ± 1400
698 ± 34
527 ± 114
Intestine
765 ± 137
5573 ± 891
30 ± 599
403 ± 118
115 ± 64
204 ± 46
Bowel
1256 ± 664
639 ± 1023
30 ± 599
3221 ± 863
125 ± 60
256 ± 102
Table 4 Pharmacolinetical parameters of 125I sodium alginate-BSA NP in rats
Parameter
Unit
Value
A
Bq
3022 × 102
α
1/h
0.07
B
Bq
3.03 × 103
β
1/h
-0.11
Ka
1/h
1.46
V/F
Bq
1428 × 103
T1/2α
h
9.42
T1/2β
h
-6.07
T1/2Ka
h
0.47
K21
1/h
-0.11
K10
1/h
0.07
K12
1/h
-0.00035
AUC
Bq × h
3.9 × 109
CL(s)
Bq × h/Bq
105 × 103
T(peak)
h
2.18
Cmax
Bq
2.45 × 107
Citation: Yi YM, Yang TY, Pan WM. Preparation and distribution of 5-fluorouracil 125I sodium alginate-bovine serum albumin nanoparticles. World J Gastroenterol 1999; 5(1): 57-60